{"title":"Topical treatment adherence and writing clarity: insights from a precision dispenser study.","authors":"Sabine L Abukhadra, Robin C Yi, Steven R Feldman","doi":"10.1080/09546634.2025.2529387","DOIUrl":"https://doi.org/10.1080/09546634.2025.2529387","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2529387"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Successful treatment of Kimura's disease with dupilumab and review of dupilumab in treating eosinophilic dermatoses.","authors":"Yunhong Zheng, Suju Luo","doi":"10.1080/09546634.2024.2449153","DOIUrl":"https://doi.org/10.1080/09546634.2024.2449153","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2449153"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meiying Tao, Tingting Gao, Lili Zhi, Naiqing Cao, Haotian Liu
{"title":"Rapid improvement of kimura disease with dupilumab in a patient with suboptimal response to mepolizumab: a case report.","authors":"Meiying Tao, Tingting Gao, Lili Zhi, Naiqing Cao, Haotian Liu","doi":"10.1080/09546634.2025.2486668","DOIUrl":"https://doi.org/10.1080/09546634.2025.2486668","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2486668"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143766278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D Orsini, D Graceffa, M Burlando, A Campanati, E Campione, C Guarneri, A Narcisi, P Pella, P Romita, M Travaglini, L Zichichi, L M H Arancio, G Baggini, R Balestri, L Bianchi, A M G Brunasso, A E Cagni, Giacomo Caldarola, G Calianno, A Carpentieri, M Carriero, A Carugno, F Cona, A Costanzo, E Cozzani, Giacomo Dal Bello, Giovanni Carlo Lazzaro Danzuso, A Dattola, A Di Tano, F Diotallevi, M Donnarumma, E De Col, M Esposito, C S Fiorella, M Galluzzo, F Graziola, M Licciardello, A Legori, P Malagoli, Federica Mola, G Moretta, A Muracchioli, A Musumeci, M L Musumeci, G Pagnanelli, V Panasiti, E Provenzano, D Rizzo, M Rubatto, Oriele Sarno, D Strippoli, F Vaira, M C Fargnoli
{"title":"Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study - IL PSO (Italian Landscape Psoriasis).","authors":"D Orsini, D Graceffa, M Burlando, A Campanati, E Campione, C Guarneri, A Narcisi, P Pella, P Romita, M Travaglini, L Zichichi, L M H Arancio, G Baggini, R Balestri, L Bianchi, A M G Brunasso, A E Cagni, Giacomo Caldarola, G Calianno, A Carpentieri, M Carriero, A Carugno, F Cona, A Costanzo, E Cozzani, Giacomo Dal Bello, Giovanni Carlo Lazzaro Danzuso, A Dattola, A Di Tano, F Diotallevi, M Donnarumma, E De Col, M Esposito, C S Fiorella, M Galluzzo, F Graziola, M Licciardello, A Legori, P Malagoli, Federica Mola, G Moretta, A Muracchioli, A Musumeci, M L Musumeci, G Pagnanelli, V Panasiti, E Provenzano, D Rizzo, M Rubatto, Oriele Sarno, D Strippoli, F Vaira, M C Fargnoli","doi":"10.1080/09546634.2025.2452948","DOIUrl":"https://doi.org/10.1080/09546634.2025.2452948","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2452948"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tofacitinib as a promising treatment for refractory erythroderma-like Hailey-Hailey disease.","authors":"Huaye Bao, Keyi Yu, Feilong An, Xin-Gang Wu","doi":"10.1080/09546634.2025.2493936","DOIUrl":"https://doi.org/10.1080/09546634.2025.2493936","url":null,"abstract":"<p><strong>Purpose: </strong>Hailey-Hailey disease (HHD), a rare autosomal dominant blistering disorder predominantly affecting intertriginous areas, is characterized by chronic relapsing courses that cause substantial morbidity. Despite multiple available therapeutic modalities, management of refractory cases remains challenging.</p><p><strong>Materials and methods: </strong>This case report details a 67-year-old male with severe erythroderma-like HHD, whose genetic analysis revealed a heterozygous nonsense mutation (c.1774C > T) in the <i>ATP2C1</i> gene. Following conventional therapies, the patient developed treatment-related complications. Therefore, oral tofacitinib was administered as an alternative treatment.</p><p><strong>Results: </strong>The patient achieved marked clinical improvement post-tofacitinib administration, with no treatment-emergent adverse events.</p><p><strong>Conclusions: </strong>This case indicates that tofacitinib may serve as a promising therapeutic option for refractory erythroderma-like HHD, particularly in cases linked to <i>ATP2C1</i> mutations.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2493936"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Georgia Marquez-Grap, Allison Kranyak, Nicholas Brownstone, John Koo
{"title":"Can pimozide kill parasites? Surprisingly, the most honest answer is 'yes'.","authors":"Georgia Marquez-Grap, Allison Kranyak, Nicholas Brownstone, John Koo","doi":"10.1080/09546634.2025.2466635","DOIUrl":"10.1080/09546634.2025.2466635","url":null,"abstract":"<p><p><b>Purpose:</b> One of the most well-known medications for treating delusional infestation (DI) is pimozide. Many patients may be reluctant to initiate treatment unless a medication has anti-pathogenic properties, as they feel otherwise it does not address their concerns regarding infestation. In this article, we explore the evidence that pimozide has a range of antipathogenic effects and how this fact can aid in patient care.</p><p><p><b>Materials and methods:</b> A scoping literature review was performed using The National Library of Medicine (PubMed). The search terms used were pimozide AND anti-microbial OR anti-bacterial OR anti-infective. All relevant articles were reviewed up to September 2024.</p><p><p><b>Results:</b> Our findings show that pimozide has antibacterial and antiparasitic effects through several unique mechanisms. Additionally, several older first-generation antipsychotics also have demonstrated anti-pathogenic properties. While the studies identified are entirely <i>in vitro</i>, the potential antipathogenic effects of pimozide may be pivotal to patients with DI as they make the critical decision to accept or reject treatment.</p><p><p><b>Conclusion:</b> With adequate disclaimers that pimozide's therapeutic efficacy may not have to do with its anti-pathogen profile, the evidence that pimozide has anti-pathogenic properties may enable dermatology providers to strengthen their therapeutic approach and alliance with patients with DI and make life-changing therapy more acceptable to the patient.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2466635"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Li Tingting, Peixin Zhang, Li Yang, Ruoyu Li, Ruojun Wang
{"title":"The effects of topical antimicrobial-corticosteroid combination therapy in comparison to topical steroids alone on the skin microbiome of patients with atopic dermatitis.","authors":"Li Tingting, Peixin Zhang, Li Yang, Ruoyu Li, Ruojun Wang","doi":"10.1080/09546634.2025.2470379","DOIUrl":"10.1080/09546634.2025.2470379","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to analyze the different therapeutic responses between topical antimicrobial-corticosteroid combination and topical corticosteroids alone on improving the skin microbiome and skin barrier of patients with atopic dermatitis (AD).</p><p><strong>Methods: </strong>Forty patients with mild-to-moderate AD were randomly assigned to receive two kinds of treatment. Skin swabs were collected from the lesional sites and nearby nonlesional sites at baseline, after topical medication treatment and 2 weeks post-treatment, and were analyzed by DNA sequencing of the fungal internal transcribed spacer (ITS)1-5 rDNA gene and the V3V4 region of the bacterial 16S rRNA gene.</p><p><strong>Results: </strong>According to our research analysis, both topical steroids alone and combination treatment of steroids and antimicrobials effectively improved the severity of AD and repaired skin barrier. AD lesions were characterized by a decreased sebum level, lower abundance of <i>Cutibacterium</i> and a higher abundance of <i>Staphylococcus</i>. A combined topical treatment with an antimicrobial and steroid showed better responses in increasing skin sebum level and restoring the skin bacterial microbiome, whereas topical steroid alone did not improve skin dysbiosis.</p><p><strong>Conclusion: </strong>A combined therapy with antimicrobial and steroid helps to recover the skin microbiome. Further studies are necessary to explore the therapeutic effects of treatments aiming at balancing the microbiome.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2470379"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Baseline hair loss severity as a potential confounder in studies on minoxidil and low-level laser therapy.","authors":"Amir Reza Akbari, Benyamin Alam, Ahmed Ageed","doi":"10.1080/09546634.2025.2506673","DOIUrl":"https://doi.org/10.1080/09546634.2025.2506673","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2506673"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe.","authors":"S Ständer, D Thaçi","doi":"10.1080/09546634.2024.2438803","DOIUrl":"10.1080/09546634.2024.2438803","url":null,"abstract":"<p><p><b>Background:</b> Psoriasis is a chronic inflammatory disease affecting about 2% of the global population, with moderate-to-severe forms requiring systemic treatment for successful disease management. By targeting the interleukin (IL)-23p19 subunit of IL-23, the master cytokine of psoriasis pathogenesis, guselkumab, tildrakizumab, and risankizumab offer improved risk-benefit profiles.</p><p><p><b>Objective:</b> While randomized clinical trials (RCTs) provide controlled data, real-world evidence (RWE) offers insights into the performance of these therapies in diverse patient populations, including those with comorbidities or difficult-to-treat areas affected. With RWE on these inhibitors constantly emerging, a comprehensive overview and expert interpretation are essential for providing key insights into psoriasis management in clinical practice.</p><p><p><b>Methods:</b> This review, therefore, examined RWE on the effectiveness and safety of IL-23p19 inhibitors compared to their pivotal RCTs.</p><p><p><b>Results:</b> Despite some gaps between RCT and RWE outcomes, particularly in underrepresented subpopulations, IL-23p19 inhibitors show strong effectiveness and favorable safety across both settings in the short- and especially in the long term, accompanied by an improvement in health-related quality of life and reduction of the main symptoms.</p><p><p><b>Conclusion:</b> Altogether, these factors make these medicines ideal treatment options. Future research should focus on improving patient-reported outcomes, specifically addressing psychological and quality-of-life aspects, to further optimize psoriasis management.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2438803"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
